Loading…
Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients
[Display omitted] Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission. To ascertain the prevalence of response and clinical remission after long...
Saved in:
| Published in: | Archivos de bronconeumología (English ed.) 2024-01, Vol.60 (1), p.23-32 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c408t-d4826f1755e3175b0e8518b445df3c266956e64599f29223805e3e6ac6672c573 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c408t-d4826f1755e3175b0e8518b445df3c266956e64599f29223805e3e6ac6672c573 |
| container_end_page | 32 |
| container_issue | 1 |
| container_start_page | 23 |
| container_title | Archivos de bronconeumología (English ed.) |
| container_volume | 60 |
| creator | Valverde-Monge, Marcela Sánchez-Carrasco, Patricia Betancor, Diana Barroso, Blanca Rodrigo-Muñoz, José Manuel Mahillo-Fernández, Ignacio Arismendi, Ebymar Bobolea, Irina Cárdaba, Blanca Cruz, María Jesús Del Pozo, Victoria Domínguez-Ortega, Javier González-Barcala, Francisco Javier Olaguibel, José María Luna-Porta, Juan Alberto Martínez-Rivera, Carlos Mullol, Joaquim Muñoz, Xavier Peleteiro-Pedraza, Lorena Picado Valles, Cesar Plaza, Vicente Quirce, Santiago Rial, Manuel Jorge Soto-Retes, Lorena Valero, Antonio Sastre, Joaquín |
| description | [Display omitted]
Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission.
To ascertain the prevalence of response and clinical remission after long-term treatment (>6 months) of anti-IgE and anti-IL-5/IL-5Rα biologics, compare these results with existing criteria, and identify predictors for non-responders and clinical remission.
A multicenter, real-life study involving severe asthma patients in Spain. Various outcomes were assessed to gauge response and clinical remission against established criteria.
The study included 429 patients, 209 (48.7%) omalizumab, 112 (26.1%) mepolizumab, 19 (4.4%) reslizumab and 89 (20.7%) benralizumab, with a mean treatment duration of 55.3±38.8 months. In the final year of treatment, 218 (50.8%) were super-responders, 173 (40.3%) responders, 38 (8.9%) non-responders, and clinical remission in 116 (27%), without differences among biologics. The short-term non-responders ( |
| doi_str_mv | 10.1016/j.arbres.2023.11.011 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2896805732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0300289623003794</els_id><sourcerecordid>2896805732</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-d4826f1755e3175b0e8518b445df3c266956e64599f29223805e3e6ac6672c573</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EokvhDRDykYtT24md5IK0ChQqrVRU6NlynHHrVWIvtrcSvEnfFoctHLmMZc33z6-ZH6G3jFaMMnmxr3QcI6SKU15XjFWUsWdow0TbE854_xxtaE0p4V0vz9CrlPaUclE3_CU6qzva8Ja2G_Q4hOWgo0vB42DxLvg7kiEu-AbSIfgEWPupfBaXkitMDvh60bP7dVz0-Ke39dmRqx0RF2u5wbfJ-Tv80VkLEXzGQ3RloNPYeazLJD2T2VnAQ7gPMa-m3-ChoHib8v2i8VedXdGl1-iF1XOCN0_vObq9_PR9-EJ215-vhu2OmIZ2mUxNx6VlrRBQlzpS6ATrxqYRk60Nl7IXEmQj-t7ynvOyeQFBaiNly41o63P0_jT3EMOPI6Ssyq4G5ll7CMek1vsVUVvzgjYn1MSQUgSrDtEtOv5UjKo1FLVXp1DUGopiTJVQiuzdk8NxXGD6J_qbQgE-nAAoez44iCqZcgMDk4tgspqC-7_Db8Ernig</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2896805732</pqid></control><display><type>article</type><title>Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients</title><source>ScienceDirect®</source><source>ScienceDirect Journals</source><creator>Valverde-Monge, Marcela ; Sánchez-Carrasco, Patricia ; Betancor, Diana ; Barroso, Blanca ; Rodrigo-Muñoz, José Manuel ; Mahillo-Fernández, Ignacio ; Arismendi, Ebymar ; Bobolea, Irina ; Cárdaba, Blanca ; Cruz, María Jesús ; Del Pozo, Victoria ; Domínguez-Ortega, Javier ; González-Barcala, Francisco Javier ; Olaguibel, José María ; Luna-Porta, Juan Alberto ; Martínez-Rivera, Carlos ; Mullol, Joaquim ; Muñoz, Xavier ; Peleteiro-Pedraza, Lorena ; Picado Valles, Cesar ; Plaza, Vicente ; Quirce, Santiago ; Rial, Manuel Jorge ; Soto-Retes, Lorena ; Valero, Antonio ; Sastre, Joaquín</creator><creatorcontrib>Valverde-Monge, Marcela ; Sánchez-Carrasco, Patricia ; Betancor, Diana ; Barroso, Blanca ; Rodrigo-Muñoz, José Manuel ; Mahillo-Fernández, Ignacio ; Arismendi, Ebymar ; Bobolea, Irina ; Cárdaba, Blanca ; Cruz, María Jesús ; Del Pozo, Victoria ; Domínguez-Ortega, Javier ; González-Barcala, Francisco Javier ; Olaguibel, José María ; Luna-Porta, Juan Alberto ; Martínez-Rivera, Carlos ; Mullol, Joaquim ; Muñoz, Xavier ; Peleteiro-Pedraza, Lorena ; Picado Valles, Cesar ; Plaza, Vicente ; Quirce, Santiago ; Rial, Manuel Jorge ; Soto-Retes, Lorena ; Valero, Antonio ; Sastre, Joaquín</creatorcontrib><description>[Display omitted]
Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission.
To ascertain the prevalence of response and clinical remission after long-term treatment (>6 months) of anti-IgE and anti-IL-5/IL-5Rα biologics, compare these results with existing criteria, and identify predictors for non-responders and clinical remission.
A multicenter, real-life study involving severe asthma patients in Spain. Various outcomes were assessed to gauge response and clinical remission against established criteria.
The study included 429 patients, 209 (48.7%) omalizumab, 112 (26.1%) mepolizumab, 19 (4.4%) reslizumab and 89 (20.7%) benralizumab, with a mean treatment duration of 55.3±38.8 months. In the final year of treatment, 218 (50.8%) were super-responders, 173 (40.3%) responders, 38 (8.9%) non-responders, and clinical remission in 116 (27%), without differences among biologics. The short-term non-responders (<6 months) were 25/545 (4.6%). Substantial variations in response and clinical remission were observed when applying different published criteria. Predictors of non-response included higher BMI (OR:1.14; 95% CI:1.06–1.23; p<0.001), admissions at ICU (2.69; 1.30–5.56; p=0.01), high count of SAE (1.21; 1.03–1.42; p=0.02) before biologic treatment. High FEV1% (0.96; 0.95–0.98; p<0.001), a high ACT score (0.93; 0.88–0.99; p=0.01) before biologic treatment or NSAID-ERD (0.52; 0.29–0.91; p=0.02) showed strong associations with achieving clinical remission.
A substantial proportion of severe asthma patients treated long-term with omalizumab or anti-IL5/IL-5Rα achieved a good response. Differences in response criteria highlight the need for harmonization in defining response and clinical remission in biologic therapy to enable meaningful cross-study comparisons.</description><identifier>ISSN: 0300-2896</identifier><identifier>EISSN: 1579-2129</identifier><identifier>DOI: 10.1016/j.arbres.2023.11.011</identifier><identifier>PMID: 38042707</identifier><language>eng</language><publisher>Spain: Elsevier España, S.L.U</publisher><subject>Anti-Asthmatic Agents ; Asthma - drug therapy ; Biologic treatment ; Biological Products - therapeutic use ; Clinical remission ; Humans ; Immunosuppressive Agents - therapeutic use ; Non-responders ; Omalizumab - therapeutic use ; Predictors ; Responders ; Severe asthma ; Severe uncontrolled asthma ; Super-responders</subject><ispartof>Archivos de bronconeumología (English ed.), 2024-01, Vol.60 (1), p.23-32</ispartof><rights>2023 SEPAR</rights><rights>Copyright © 2023 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-d4826f1755e3175b0e8518b445df3c266956e64599f29223805e3e6ac6672c573</citedby><cites>FETCH-LOGICAL-c408t-d4826f1755e3175b0e8518b445df3c266956e64599f29223805e3e6ac6672c573</cites><orcidid>0000-0001-9759-5466 ; 0000-0002-9126-4559 ; 0000-0003-0142-9901 ; 0000-0001-6228-1969 ; 0000-0003-0558-6541 ; 0000-0003-0280-0143 ; 0000-0003-4689-6837 ; 0000-0003-2765-3581 ; 0000-0003-3873-4563 ; 0000-0002-7749-2838 ; 0000-0003-4706-6608 ; 0000-0002-0172-3951 ; 0000-0003-3463-5007 ; 0000-0003-2695-8439 ; 0000-0003-2567-5496 ; 0000-0001-5847-4784 ; 0000-0001-8086-0921 ; 0000-0002-8338-0883 ; 0000-0002-5397-2327 ; 0000-0002-7425-2417</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0300289623003794$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27924,27925,45780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38042707$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Valverde-Monge, Marcela</creatorcontrib><creatorcontrib>Sánchez-Carrasco, Patricia</creatorcontrib><creatorcontrib>Betancor, Diana</creatorcontrib><creatorcontrib>Barroso, Blanca</creatorcontrib><creatorcontrib>Rodrigo-Muñoz, José Manuel</creatorcontrib><creatorcontrib>Mahillo-Fernández, Ignacio</creatorcontrib><creatorcontrib>Arismendi, Ebymar</creatorcontrib><creatorcontrib>Bobolea, Irina</creatorcontrib><creatorcontrib>Cárdaba, Blanca</creatorcontrib><creatorcontrib>Cruz, María Jesús</creatorcontrib><creatorcontrib>Del Pozo, Victoria</creatorcontrib><creatorcontrib>Domínguez-Ortega, Javier</creatorcontrib><creatorcontrib>González-Barcala, Francisco Javier</creatorcontrib><creatorcontrib>Olaguibel, José María</creatorcontrib><creatorcontrib>Luna-Porta, Juan Alberto</creatorcontrib><creatorcontrib>Martínez-Rivera, Carlos</creatorcontrib><creatorcontrib>Mullol, Joaquim</creatorcontrib><creatorcontrib>Muñoz, Xavier</creatorcontrib><creatorcontrib>Peleteiro-Pedraza, Lorena</creatorcontrib><creatorcontrib>Picado Valles, Cesar</creatorcontrib><creatorcontrib>Plaza, Vicente</creatorcontrib><creatorcontrib>Quirce, Santiago</creatorcontrib><creatorcontrib>Rial, Manuel Jorge</creatorcontrib><creatorcontrib>Soto-Retes, Lorena</creatorcontrib><creatorcontrib>Valero, Antonio</creatorcontrib><creatorcontrib>Sastre, Joaquín</creatorcontrib><title>Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients</title><title>Archivos de bronconeumología (English ed.)</title><addtitle>Arch Bronconeumol</addtitle><description>[Display omitted]
Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission.
To ascertain the prevalence of response and clinical remission after long-term treatment (>6 months) of anti-IgE and anti-IL-5/IL-5Rα biologics, compare these results with existing criteria, and identify predictors for non-responders and clinical remission.
A multicenter, real-life study involving severe asthma patients in Spain. Various outcomes were assessed to gauge response and clinical remission against established criteria.
The study included 429 patients, 209 (48.7%) omalizumab, 112 (26.1%) mepolizumab, 19 (4.4%) reslizumab and 89 (20.7%) benralizumab, with a mean treatment duration of 55.3±38.8 months. In the final year of treatment, 218 (50.8%) were super-responders, 173 (40.3%) responders, 38 (8.9%) non-responders, and clinical remission in 116 (27%), without differences among biologics. The short-term non-responders (<6 months) were 25/545 (4.6%). Substantial variations in response and clinical remission were observed when applying different published criteria. Predictors of non-response included higher BMI (OR:1.14; 95% CI:1.06–1.23; p<0.001), admissions at ICU (2.69; 1.30–5.56; p=0.01), high count of SAE (1.21; 1.03–1.42; p=0.02) before biologic treatment. High FEV1% (0.96; 0.95–0.98; p<0.001), a high ACT score (0.93; 0.88–0.99; p=0.01) before biologic treatment or NSAID-ERD (0.52; 0.29–0.91; p=0.02) showed strong associations with achieving clinical remission.
A substantial proportion of severe asthma patients treated long-term with omalizumab or anti-IL5/IL-5Rα achieved a good response. Differences in response criteria highlight the need for harmonization in defining response and clinical remission in biologic therapy to enable meaningful cross-study comparisons.</description><subject>Anti-Asthmatic Agents</subject><subject>Asthma - drug therapy</subject><subject>Biologic treatment</subject><subject>Biological Products - therapeutic use</subject><subject>Clinical remission</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Non-responders</subject><subject>Omalizumab - therapeutic use</subject><subject>Predictors</subject><subject>Responders</subject><subject>Severe asthma</subject><subject>Severe uncontrolled asthma</subject><subject>Super-responders</subject><issn>0300-2896</issn><issn>1579-2129</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhi0EokvhDRDykYtT24md5IK0ChQqrVRU6NlynHHrVWIvtrcSvEnfFoctHLmMZc33z6-ZH6G3jFaMMnmxr3QcI6SKU15XjFWUsWdow0TbE854_xxtaE0p4V0vz9CrlPaUclE3_CU6qzva8Ja2G_Q4hOWgo0vB42DxLvg7kiEu-AbSIfgEWPupfBaXkitMDvh60bP7dVz0-Ke39dmRqx0RF2u5wbfJ-Tv80VkLEXzGQ3RloNPYeazLJD2T2VnAQ7gPMa-m3-ChoHib8v2i8VedXdGl1-iF1XOCN0_vObq9_PR9-EJ215-vhu2OmIZ2mUxNx6VlrRBQlzpS6ATrxqYRk60Nl7IXEmQj-t7ynvOyeQFBaiNly41o63P0_jT3EMOPI6Ssyq4G5ll7CMek1vsVUVvzgjYn1MSQUgSrDtEtOv5UjKo1FLVXp1DUGopiTJVQiuzdk8NxXGD6J_qbQgE-nAAoez44iCqZcgMDk4tgspqC-7_Db8Ernig</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Valverde-Monge, Marcela</creator><creator>Sánchez-Carrasco, Patricia</creator><creator>Betancor, Diana</creator><creator>Barroso, Blanca</creator><creator>Rodrigo-Muñoz, José Manuel</creator><creator>Mahillo-Fernández, Ignacio</creator><creator>Arismendi, Ebymar</creator><creator>Bobolea, Irina</creator><creator>Cárdaba, Blanca</creator><creator>Cruz, María Jesús</creator><creator>Del Pozo, Victoria</creator><creator>Domínguez-Ortega, Javier</creator><creator>González-Barcala, Francisco Javier</creator><creator>Olaguibel, José María</creator><creator>Luna-Porta, Juan Alberto</creator><creator>Martínez-Rivera, Carlos</creator><creator>Mullol, Joaquim</creator><creator>Muñoz, Xavier</creator><creator>Peleteiro-Pedraza, Lorena</creator><creator>Picado Valles, Cesar</creator><creator>Plaza, Vicente</creator><creator>Quirce, Santiago</creator><creator>Rial, Manuel Jorge</creator><creator>Soto-Retes, Lorena</creator><creator>Valero, Antonio</creator><creator>Sastre, Joaquín</creator><general>Elsevier España, S.L.U</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9759-5466</orcidid><orcidid>https://orcid.org/0000-0002-9126-4559</orcidid><orcidid>https://orcid.org/0000-0003-0142-9901</orcidid><orcidid>https://orcid.org/0000-0001-6228-1969</orcidid><orcidid>https://orcid.org/0000-0003-0558-6541</orcidid><orcidid>https://orcid.org/0000-0003-0280-0143</orcidid><orcidid>https://orcid.org/0000-0003-4689-6837</orcidid><orcidid>https://orcid.org/0000-0003-2765-3581</orcidid><orcidid>https://orcid.org/0000-0003-3873-4563</orcidid><orcidid>https://orcid.org/0000-0002-7749-2838</orcidid><orcidid>https://orcid.org/0000-0003-4706-6608</orcidid><orcidid>https://orcid.org/0000-0002-0172-3951</orcidid><orcidid>https://orcid.org/0000-0003-3463-5007</orcidid><orcidid>https://orcid.org/0000-0003-2695-8439</orcidid><orcidid>https://orcid.org/0000-0003-2567-5496</orcidid><orcidid>https://orcid.org/0000-0001-5847-4784</orcidid><orcidid>https://orcid.org/0000-0001-8086-0921</orcidid><orcidid>https://orcid.org/0000-0002-8338-0883</orcidid><orcidid>https://orcid.org/0000-0002-5397-2327</orcidid><orcidid>https://orcid.org/0000-0002-7425-2417</orcidid></search><sort><creationdate>202401</creationdate><title>Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients</title><author>Valverde-Monge, Marcela ; Sánchez-Carrasco, Patricia ; Betancor, Diana ; Barroso, Blanca ; Rodrigo-Muñoz, José Manuel ; Mahillo-Fernández, Ignacio ; Arismendi, Ebymar ; Bobolea, Irina ; Cárdaba, Blanca ; Cruz, María Jesús ; Del Pozo, Victoria ; Domínguez-Ortega, Javier ; González-Barcala, Francisco Javier ; Olaguibel, José María ; Luna-Porta, Juan Alberto ; Martínez-Rivera, Carlos ; Mullol, Joaquim ; Muñoz, Xavier ; Peleteiro-Pedraza, Lorena ; Picado Valles, Cesar ; Plaza, Vicente ; Quirce, Santiago ; Rial, Manuel Jorge ; Soto-Retes, Lorena ; Valero, Antonio ; Sastre, Joaquín</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-d4826f1755e3175b0e8518b445df3c266956e64599f29223805e3e6ac6672c573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anti-Asthmatic Agents</topic><topic>Asthma - drug therapy</topic><topic>Biologic treatment</topic><topic>Biological Products - therapeutic use</topic><topic>Clinical remission</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Non-responders</topic><topic>Omalizumab - therapeutic use</topic><topic>Predictors</topic><topic>Responders</topic><topic>Severe asthma</topic><topic>Severe uncontrolled asthma</topic><topic>Super-responders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Valverde-Monge, Marcela</creatorcontrib><creatorcontrib>Sánchez-Carrasco, Patricia</creatorcontrib><creatorcontrib>Betancor, Diana</creatorcontrib><creatorcontrib>Barroso, Blanca</creatorcontrib><creatorcontrib>Rodrigo-Muñoz, José Manuel</creatorcontrib><creatorcontrib>Mahillo-Fernández, Ignacio</creatorcontrib><creatorcontrib>Arismendi, Ebymar</creatorcontrib><creatorcontrib>Bobolea, Irina</creatorcontrib><creatorcontrib>Cárdaba, Blanca</creatorcontrib><creatorcontrib>Cruz, María Jesús</creatorcontrib><creatorcontrib>Del Pozo, Victoria</creatorcontrib><creatorcontrib>Domínguez-Ortega, Javier</creatorcontrib><creatorcontrib>González-Barcala, Francisco Javier</creatorcontrib><creatorcontrib>Olaguibel, José María</creatorcontrib><creatorcontrib>Luna-Porta, Juan Alberto</creatorcontrib><creatorcontrib>Martínez-Rivera, Carlos</creatorcontrib><creatorcontrib>Mullol, Joaquim</creatorcontrib><creatorcontrib>Muñoz, Xavier</creatorcontrib><creatorcontrib>Peleteiro-Pedraza, Lorena</creatorcontrib><creatorcontrib>Picado Valles, Cesar</creatorcontrib><creatorcontrib>Plaza, Vicente</creatorcontrib><creatorcontrib>Quirce, Santiago</creatorcontrib><creatorcontrib>Rial, Manuel Jorge</creatorcontrib><creatorcontrib>Soto-Retes, Lorena</creatorcontrib><creatorcontrib>Valero, Antonio</creatorcontrib><creatorcontrib>Sastre, Joaquín</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Archivos de bronconeumología (English ed.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Valverde-Monge, Marcela</au><au>Sánchez-Carrasco, Patricia</au><au>Betancor, Diana</au><au>Barroso, Blanca</au><au>Rodrigo-Muñoz, José Manuel</au><au>Mahillo-Fernández, Ignacio</au><au>Arismendi, Ebymar</au><au>Bobolea, Irina</au><au>Cárdaba, Blanca</au><au>Cruz, María Jesús</au><au>Del Pozo, Victoria</au><au>Domínguez-Ortega, Javier</au><au>González-Barcala, Francisco Javier</au><au>Olaguibel, José María</au><au>Luna-Porta, Juan Alberto</au><au>Martínez-Rivera, Carlos</au><au>Mullol, Joaquim</au><au>Muñoz, Xavier</au><au>Peleteiro-Pedraza, Lorena</au><au>Picado Valles, Cesar</au><au>Plaza, Vicente</au><au>Quirce, Santiago</au><au>Rial, Manuel Jorge</au><au>Soto-Retes, Lorena</au><au>Valero, Antonio</au><au>Sastre, Joaquín</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients</atitle><jtitle>Archivos de bronconeumología (English ed.)</jtitle><addtitle>Arch Bronconeumol</addtitle><date>2024-01</date><risdate>2024</risdate><volume>60</volume><issue>1</issue><spage>23</spage><epage>32</epage><pages>23-32</pages><issn>0300-2896</issn><eissn>1579-2129</eissn><abstract>[Display omitted]
Evaluation of biologic therapy response is vital to monitor its effectiveness. Authors have proposed various response criteria including good responder, super-responder, non-responder, and clinical remission.
To ascertain the prevalence of response and clinical remission after long-term treatment (>6 months) of anti-IgE and anti-IL-5/IL-5Rα biologics, compare these results with existing criteria, and identify predictors for non-responders and clinical remission.
A multicenter, real-life study involving severe asthma patients in Spain. Various outcomes were assessed to gauge response and clinical remission against established criteria.
The study included 429 patients, 209 (48.7%) omalizumab, 112 (26.1%) mepolizumab, 19 (4.4%) reslizumab and 89 (20.7%) benralizumab, with a mean treatment duration of 55.3±38.8 months. In the final year of treatment, 218 (50.8%) were super-responders, 173 (40.3%) responders, 38 (8.9%) non-responders, and clinical remission in 116 (27%), without differences among biologics. The short-term non-responders (<6 months) were 25/545 (4.6%). Substantial variations in response and clinical remission were observed when applying different published criteria. Predictors of non-response included higher BMI (OR:1.14; 95% CI:1.06–1.23; p<0.001), admissions at ICU (2.69; 1.30–5.56; p=0.01), high count of SAE (1.21; 1.03–1.42; p=0.02) before biologic treatment. High FEV1% (0.96; 0.95–0.98; p<0.001), a high ACT score (0.93; 0.88–0.99; p=0.01) before biologic treatment or NSAID-ERD (0.52; 0.29–0.91; p=0.02) showed strong associations with achieving clinical remission.
A substantial proportion of severe asthma patients treated long-term with omalizumab or anti-IL5/IL-5Rα achieved a good response. Differences in response criteria highlight the need for harmonization in defining response and clinical remission in biologic therapy to enable meaningful cross-study comparisons.</abstract><cop>Spain</cop><pub>Elsevier España, S.L.U</pub><pmid>38042707</pmid><doi>10.1016/j.arbres.2023.11.011</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-9759-5466</orcidid><orcidid>https://orcid.org/0000-0002-9126-4559</orcidid><orcidid>https://orcid.org/0000-0003-0142-9901</orcidid><orcidid>https://orcid.org/0000-0001-6228-1969</orcidid><orcidid>https://orcid.org/0000-0003-0558-6541</orcidid><orcidid>https://orcid.org/0000-0003-0280-0143</orcidid><orcidid>https://orcid.org/0000-0003-4689-6837</orcidid><orcidid>https://orcid.org/0000-0003-2765-3581</orcidid><orcidid>https://orcid.org/0000-0003-3873-4563</orcidid><orcidid>https://orcid.org/0000-0002-7749-2838</orcidid><orcidid>https://orcid.org/0000-0003-4706-6608</orcidid><orcidid>https://orcid.org/0000-0002-0172-3951</orcidid><orcidid>https://orcid.org/0000-0003-3463-5007</orcidid><orcidid>https://orcid.org/0000-0003-2695-8439</orcidid><orcidid>https://orcid.org/0000-0003-2567-5496</orcidid><orcidid>https://orcid.org/0000-0001-5847-4784</orcidid><orcidid>https://orcid.org/0000-0001-8086-0921</orcidid><orcidid>https://orcid.org/0000-0002-8338-0883</orcidid><orcidid>https://orcid.org/0000-0002-5397-2327</orcidid><orcidid>https://orcid.org/0000-0002-7425-2417</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-2896 |
| ispartof | Archivos de bronconeumología (English ed.), 2024-01, Vol.60 (1), p.23-32 |
| issn | 0300-2896 1579-2129 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2896805732 |
| source | ScienceDirect®; ScienceDirect Journals |
| subjects | Anti-Asthmatic Agents Asthma - drug therapy Biologic treatment Biological Products - therapeutic use Clinical remission Humans Immunosuppressive Agents - therapeutic use Non-responders Omalizumab - therapeutic use Predictors Responders Severe asthma Severe uncontrolled asthma Super-responders |
| title | Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A27%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Long-term%20Response%20and%20Remission%20to%20Omalizumab%20and%20Anti-IL-5/IL-5R%20Using%20Different%20Criteria%20in%20a%20Real-life%20Cohort%20of%20Severe%20Asthma%20Patients&rft.jtitle=Archivos%20de%20bronconeumologi%CC%81a%20(English%20ed.)&rft.au=Valverde-Monge,%20Marcela&rft.date=2024-01&rft.volume=60&rft.issue=1&rft.spage=23&rft.epage=32&rft.pages=23-32&rft.issn=0300-2896&rft.eissn=1579-2129&rft_id=info:doi/10.1016/j.arbres.2023.11.011&rft_dat=%3Cproquest_cross%3E2896805732%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c408t-d4826f1755e3175b0e8518b445df3c266956e64599f29223805e3e6ac6672c573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2896805732&rft_id=info:pmid/38042707&rfr_iscdi=true |